Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | FNTA | P49354 | 2/20 | 0.33 |
| ▸ | FNTB | P49356 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1972804 | 1.00 | AOC3 (0.59) | AOC3CYP2D6HTTCHRM4CHRM5 | |
| SCHEMBL12312304 | 0.83 | AOC3 (0.41) | AOC3CYP2D6HTTCHRM4CHRM5 | |
| SCHEMBL2345151 | 0.82 | AOC3 (0.71) | AOC3 | |
| SCHEMBL2345148 | 0.82 | AOC3 (0.71) | AOC3 | |
| SCHEMBL18953100 | 0.82 | AOC3 (0.71) | AOC3 | |
| SCHEMBL3126584 | 0.82 | AOC3 (0.71) | AOC3 | |
| SCHEMBL1976869 | 0.78 | AOC3 (0.64) | AOC3ALDH1A1POLB | |
| SCHEMBL18953107 | 0.77 | AOC3 (0.62) | AOC3ALDH1A1POLB | |
| SCHEMBL12094922 | 0.77 | AOC3 (0.65) | AOC3ALDH1A1POLB | |
| SCHEMBL1973686 | 0.77 | AOC3 (0.65) | AOC3ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118744-A1 | NEW COMPOUNDS I | PROXIMAGEN LIMITED (GB) | 2018-05-03 | — | — | US | claimed |
| US-9890160-B2 | Compounds I | PROXIMAGEN LIMITED (GB) | 2018-02-13 | — | — | US | claimed |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | claimed |
| US-20110207746-A1 | NEW COMPOUNDS I | PROXIMAGEN LIMITED (GB) | 2011-08-25 | — | — | US | claimed |
| US-11040969-B2 | Compounds I | Benevolentai Cambridge Limited (GB) | 2021-06-22 | — | — | US | disclosed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-10399973-B2 | Compounds I | Benevolentai Cambridge Limited (GB) | 2019-09-03 | — | — | US | disclosed |
| US-20180118744-A1 | NEW COMPOUNDS I | PROXIMAGEN LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9890160-B2 | Compounds I | PROXIMAGEN LIMITED (GB) | 2018-02-13 | — | — | US | disclosed |
| US-20170044157-A1 | NEW COMPOUNDS I | PROXIMAGEN, LLC | 2017-02-16 | — | — | US | disclosed |
| US-9493457-B2 | 4,5,6,7-tetrahyroimidazo[4,5-c]pyridine compounds | PROXIMAGEN LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-20150218161-A1 | NEW COMPOUNDS I | PROXIMAGEN, LLC | 2015-08-06 | — | — | US | disclosed |
| EP-2334672-A1 | NEW COMPOUNDS I | Proximagen Limited (GB) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010031789-A1 | NEW COMPOUNDS I | BIOVITRUM AB (PUBL) (SE) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399973-B2 | Compounds I | SSB, SQLE, ALOX15B | AOC3 63/4885CYP2D6 132/4885HTT 1135/4885 |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | VAPB, VAPA, AOX1 | AOC3 24/4885CYP2D6 2647/4885HTT 1171/4885 |
| US-20110207746-A1 | NEW COMPOUNDS I | SSB, NFKBIA, ALOX15B | AOC3 54/4885CYP2D6 141/4885HTT 1533/4885 |
| US-11040969-B2 | Compounds I | SSB, SQLE, ALOX15B | AOC3 63/4885CYP2D6 132/4885HTT 1135/4885 |
| US-20170044157-A1 | NEW COMPOUNDS I | SSB, NFKBIA, ALOX15B | AOC3 54/4885CYP2D6 141/4885HTT 1533/4885 |
| US-20180118744-A1 | NEW COMPOUNDS I | SSB, NFKBIA, ALOX15B | AOC3 54/4885CYP2D6 141/4885HTT 1533/4885 |
| US-20150218161-A1 | NEW COMPOUNDS I | SSB, NFKBIA, ALOX15B | AOC3 54/4885CYP2D6 141/4885HTT 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.